Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 401 to 425 of 1152 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
1037 increased gene conversion of immunoglobulin genes (GO:0002206) B cell receptor complex (GO:0019815) None
1053 occurrence gene conversion of immunoglobulin genes (GO:0002206) B cell receptor complex (GO:0019815) 2254: Gluten-reactive and transglutaminase 2 reactive B cell receptors, generation
1150 increased Abnormality of cellular immune system (HP:0010987) B7-related protein (PR:000001290) 2323: Over-expression of PD-L1 in cancer cells
839 disrupted barrier epithelial cell (CL:0000073) 1931: Intestinal barrier, disruption
555 increased cell proliferation (GO:0008283) basal cell (CL:0000646) 1067: Proliferation/Clonal Expansion, aberrant basal-type cells
609 increased catalytic activity (GO:0003824) beta-1,3-glucuronyltransferase (PR:000001325) 295: Induction, Upregulation of glucuronyltransferase activity
39 increased glucuronosyltransferase activity (GO:0015020) beta-1,3-glucuronyltransferase (PR:000001325) 295: Induction, Upregulation of glucuronyltransferase activity
538 increased beta-2 adrenergic receptor binding (GO:0031698) beta-2 adrenergic receptor (PR:000001193) 1038: Activation, beta-2 adrenergic receptor
539 increased beta2-adrenergic receptor activity (GO:0004941) beta-2 adrenergic receptor (PR:000001193) 1039: Increased activity, beta-2 adrenergic receptor
771 occurrence regulation of beta-catenin-TCF complex assembly (GO:1904863) beta-catenin-TCF complex (GO:1990907) 1755: beta-catenin activation
626 increased cytokine production (GO:0001816) beta-nerve growth factor (PR:000011194) 1234: Production of nerve growth factor , Epithelial irritation
549 decreased bile (UBERON:0001970) 1058: Decreased, bile flow
126 increased bile (UBERON:0001970) 214: Bile accumulation, Pathological condition
125 increased gene expression (GO:0010467) bile acid receptor (PR:000011396) 288: Activation of specific nuclear receptors, Transcriptional change
255 increased signaling (GO:0023052) bile acid receptor (PR:000011396) 479: Activation, NR1H4
212 increased Bile Duct Neoplasms (MESH:D001650) 856: Formation, Hepatocellular and Bile duct tumors
124 decreased transport (GO:0006810) bile salt export pump (PR:000003549) 41: Inhibition, Bile Salt Export Pump (ABCB11)
731 decreased fin regeneration (GO:0031101) blastemal cell (CL:0000354) 1761: Inhibition, Fin regeneration
912 occurrence abnormal blood coagulation (MP:0002551) blood (UBERON:0000178) 1845: Coagulation
221 decreased blood circulation (GO:0008015) blood (UBERON:0000178) 298: Insufficiency, Vascular
989 increased blood viscosity trait (VT:3000004) blood (UBERON:0000178) 2238: Increased, Blood viscosity
589 decreased blood coagulation factors (MESH:D001779) 1133: Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1015 decreased regulation of body fluid levels (GO:0050878) blood plasma (UBERON:0001969) None
1017 decreased decreased circulating sodium level (MP:0005634) blood plasma (UBERON:0001969) 2237: Decreased, Plasma sodium concentrations
1018 decreased blood circulation (GO:0008015) blood plasma (UBERON:0001969) 2261: Decreased, blood plasma volume